Startup Opportunities in Biotechnology

Richard Scheller, Genentech

Loading video...

Richard Scheller, Genentech's Executive Vice President of Research and Early Development, believes it is unlikely, if not impossible, for small companies to push drug products through the final stage of development. However, Scheller also thinks a smart biotechnology startup could do early stage development and then turn to larger firms for product licensing or acquisition. Scheller also discusses the state of research and development at Genentech, in comparison to other firms.

Apr 27, 2011

More from this event

More on this topic